net2phone Adquiere Integra, Una Plataforma de CCaaS Omnicanal
03 mars 2022 17h10 HE
|
net2phone
net2phone fortalece su status de proveedor líder de comunicaciones en la nube y soluciones colaborativas Newark, NJ, March 03, 2022 (GLOBE NEWSWIRE) -- net2phone, empresa líder en comunicaciones...
net2phone adquire a Integra, plataforma Contact Center Omnichan-nel
03 mars 2022 17h10 HE
|
net2phone
net2phone fortalece seu status como fornecedor líder de comunicações em nuvem e solu-ções colaborativas Newark, NJ, March 03, 2022 (GLOBE NEWSWIRE) -- A net2phone, empresa líder em comunicações...
net2phone Acquires Integra, an Omnichannel CCaaS Platform
03 mars 2022 17h10 HE
|
net2phone
net2phone strengthens its position as a leading provider of cloud communications and collaboration solutions Newark, NJ, March 03, 2022 (GLOBE NEWSWIRE) -- net2phone, a leading...
Dallas, Texas is the Home of Command Alkon’s Annual Spring TRAININGDAYS
18 févr. 2020 10h06 HE
|
Command Alkon
BIRMINGHAM, Ala., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Command Alkon, the leading Supplier Collaboration Platform for Construction’s Heavy Work, will offer their annual Spring TRAININGDAYS Regional...
Integra Reports on Positive Metallurgical Test-work Program Ongoing at DeLamar and Florida Mountain Deposits
08 avr. 2019 06h00 HE
|
Integra Resources Corp.
Press Release Highlights: Oxidation boundaries on the NI 43-101 inferred resource estimate at DeLamar and Florida Mountain are estimated at:• 24% oxide mineralization• 29% transitional...
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
05 févr. 2019 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
20 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
17 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
06 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
04 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...